Sin spam. Cancela en cualquier momento.
Análisis de Pureza HPLC
HGH
CAS: 12629-01-5
Estudiado para la restauración de vías de recuperación relacionadas con la edad
HGH es un péptido de investigación en la categoría de hormona de crecimiento / secretagogos de GH. HGH es una proteína de 191 aminoácidos sintetizada en la pituitaria anterior que se une a los receptores de hormona de crecimiento (GHR) en los tejidos diana, activando la señalización JAK2/STAT5. MiPeptidos ofrece HGH en 6 tamaños con 99.2% de pureza verificada y documentación analítica completa.
- Mejor composición corporal
- Sueño más profundo y reparador
- Recuperación más rápida del ejercicio
- Mejor calidad de piel y cabello
En las semanas 1-4, los estudios reportan mejora en la calidad del sueño y aumento de energía dentro de las primeras 1-2 semanas, con mejoras sutiles en la piel. Entre las semanas 5-12, la investigación sugiere una reducción medible de la grasa corporal y aumento de la masa muscular magra. Las semanas 13-24 traen mejoras continuas en la composición corporal, mejores marcadores de densidad ósea y mejoras visibles en la elasticidad de la piel y calidad del cabello.
$16.80/vial · Everything you need to start
Sin spam. Cancela en cualquier momento.
Análisis de Pureza HPLC
Restore Peak Performance.
24-week growth hormone protocol backed by 6 landmark clinical trials and decades of endocrine research
Recombinant human growth hormone (rhGH/somatropin) is a 191-amino acid protein identical to endogenous pituitary GH. It is one of the most extensively studied hormones in medicine, with FDA-approved indications for growth hormone deficiency in both children and adults, and decades of clinical data on body composition, bone density, and metabolic optimization.
Resultados Publicados
Revisado por ParesResultados cuantificables de investigación clínica publicada.
Lo que Dicen los Expertos
4 MédicosProfesionales e investigadores líderes que han estudiado y prescrito este péptido.
Dr. Thierry Hertoghe
President, International Hormone Society
Fourth-generation endocrinologist. Author of 'The Hormone Handbook' and 'Growth Hormone: Reversing Human Aging Naturally.' 40+ years in hormone replacement therapy.
Growth hormone is the body's master repair hormone. It declines roughly 14% per decade after age 30, driving sarcopenia, visceral fat accumulation, and diminished recovery.
0.5–2 IU/day subcutaneous for anti-aging. Start low and titrate based on IGF-1 levels. Evening dosing mimics physiological pulsatility. Monitor IGF-1 every 6–8 weeks.
Fuente: The Hormone Handbook (ISBN: 978-2930355078)
Dr. Mark Gordon
Medical Director, Millennium Health Centers
Interventional endocrinologist specializing in traumatic brain injury and neuroendocrine dysfunction. Author of 'The Clinical Application of Interventional Endocrinology.' 25+ years clinical experience.
Growth hormone deficiency is one of the most underdiagnosed conditions in adults. Restoring the GH/IGF-1 axis transforms body composition, cognitive function, and recovery capacity.
1–2 IU/day for adults with documented GH deficiency. Subcutaneous injection before bed. Target IGF-1 at upper quartile of age-adjusted range. Cycle 5 days on, 2 days off to maintain pituitary sensitivity.
Fuente: The Joe Rogan Experience #1589; Clinical Application of Interventional Endocrinology
Dr. Ron Rothenberg
Clinical Professor, University of California San Diego
Board-certified in emergency medicine and anti-aging medicine. Founder of California HealthSpan Institute. Fellow of the American Academy of Anti-Aging Medicine (A4M).
Low-dose growth hormone replacement in adults with documented deficiency improves lean mass, reduces visceral fat, enhances bone density, and significantly improves quality of life metrics.
Start at 0.5 IU/day, titrate to 1–3 IU/day based on IGF-1 monitoring. Subcutaneous injection in the evening. Regular metabolic panels including fasting glucose and insulin.
Fuente: California HealthSpan Institute Protocols; A4M Fellowship Lectures
Dr. Andrew Huberman
Professor of Neurobiology, Stanford University
Ph.D. in Neuroscience. Host of Huberman Lab, one of the most popular science podcasts globally.
Growth hormone released during deep sleep is critical for tissue repair and cognitive function. Optimizing the GH pulse during slow-wave sleep may be the most impactful intervention for longevity.
Prioritize endogenous GH optimization first: cold exposure, high-intensity exercise, adequate deep sleep. If supplementing, lowest effective dose with careful IGF-1 monitoring. Avoid chronic supraphysiological levels.
Fuente: Huberman Lab Podcast: How to Optimize Your Growth Hormone (2023)
Protocolo de Dosificación
3 FasesRégimen de dosificación paso a paso compilado de profesionales líderes e investigación clínica.
Start at 1 IU to assess tolerance. Allows adaptation and minimizes water retention and joint discomfort. Check IGF-1 at week 4.
Titrate based on IGF-1 levels (target upper-normal range for age). Split dosing (AM + PM) if using >3 IU. Monitor fasting glucose quarterly.
Reduced dose for long-term maintenance. Continue IGF-1 monitoring every 8–12 weeks. Cycle off entirely for 4–8 weeks annually to maintain pituitary sensitivity.
Add 1 mL bacteriostatic water per 10 IU vial. 1 IU = 10 units on insulin syringe; 2 IU = 20 units. Gently swirl — never shake.
Standard: 5 days on, 2 days off. Extended: 6 months on, 1–2 months off. Some practitioners run continuous low-dose (1–2 IU) year-round with monitoring.
Lyophilized: -20°C for 24+ months. Reconstituted: 2–8°C, use within 21 days. Extremely sensitive to heat — never freeze reconstituted solution.
Subcutaneous injection preferred. Evening dosing (30–60 min before bed) mimics natural nocturnal GH pulse. Rotate injection sites to prevent lipodystrophy. Fasted state enhances absorption.
Cronología de Recuperación
Basado en observaciones de investigación publicada. Los resultados individuales varían. Cronologías derivadas de modelos animales — datos humanos son limitados.
Metabolic Adaptation & Initial Response
- Improved sleep quality and deeper slow-wave sleep within 1–2 weeks
- Mild water retention and joint stiffness (transient, resolves by week 3–4)
- Increased energy levels and enhanced recovery from exercise
- IGF-1 levels begin to rise within 48–72 hours of first dose
- Subtle improvements in skin hydration and texture
Base de investigación: Jorgensen et al. (1989) Lancet; Cuneo et al. (1998) J Clin Endocrinol Metab
Body Composition Remodeling
- Measurable reduction in visceral adipose tissue (VAT)
- Increased lean body mass (1–3 kg typical in GH-deficient adults)
- Enhanced exercise capacity and VO2 improvements
- Improved cholesterol profile — reduced LDL, increased HDL
- Accelerated wound healing and recovery from training
Base de investigación: Salomon et al. (1989) NEJM; Johannsson et al. (1997) J Clin Endocrinol Metab
Structural & Functional Optimization
- Continued fat loss with lean mass preservation
- Measurable bone mineral density improvements begin
- Collagen synthesis and skin elasticity improvements notable
- Improved cognitive function and mood stability reported
- Hair and nail growth acceleration observed
Base de investigación: Gotherstrom et al. (2001) J Clin Endocrinol Metab; Hazem et al. (2012) J Clin Endocrinol Metab
Maintenance & Long-Term Adaptation
- Body composition gains stabilize at maintenance dosing
- Bone density improvements continue for 12+ months
- Cardiovascular risk markers maintain improvement
- Quality of life metrics remain elevated per QoL-AGHDA scores
Base de investigación: Gotherstrom et al. (2009) Eur J Endocrinol; Appelman-Dijkstra et al. (2014) J Bone Miner Res
Mecanismo de Acción
4 vías biológicas distintas a través de las cuales opera este péptido.
JAK2/STAT5 Signaling Cascade
HGH binds GHR, causing receptor dimerization and activation of JAK2 kinase, which phosphorylates STAT5b to drive gene transcription for growth, repair, and IGF-1 production.
- GHR dimerization activates Janus kinase 2 (JAK2) within seconds
- STAT5b phosphorylation drives hepatic IGF-1 gene transcription
- Also activates MAPK and PI3K/Akt pathways for cell survival
Brooks & Waters (2010) Nat Rev Endocrinol; PMID: 20098448
Hepatic IGF-1 Production
GH stimulates the liver to produce IGF-1, which circulates bound to IGFBPs and mediates the majority of GH's anabolic and growth-promoting effects on peripheral tissues.
- Liver produces ~75% of circulating IGF-1 in response to GH
- IGF-1 has a half-life of ~15 hours (vs 2–3 hours for GH)
- IGFBP-3 and ALS form a ternary complex extending IGF-1 activity
Le Roith et al. (2001) Endocr Rev; PMID: 11739329
Lipolysis & Fat Oxidation
GH directly stimulates lipolysis in adipocytes through hormone-sensitive lipase (HSL) activation, increasing free fatty acid oxidation and reducing visceral adipose tissue.
- Activates hormone-sensitive lipase via beta-adrenergic-independent pathway
- Promotes fatty acid oxidation over glucose utilization
- Preferentially targets visceral adipose tissue (VAT) over subcutaneous fat
Møller & Jørgensen (2009) J Clin Endocrinol Metab; PMID: 19454582
Protein Synthesis & Nitrogen Retention
GH enhances amino acid uptake and protein synthesis in skeletal muscle through both direct GHR signaling and IGF-1-mediated mTOR pathway activation.
- Increases nitrogen retention and amino acid transport into muscle cells
- IGF-1 activates PI3K/Akt/mTOR for ribosomal biogenesis and translation
- Anti-catabolic effects — inhibits protein breakdown during caloric deficit
Fryburg et al. (1991) Am J Physiol; PMID: 1872399
Investigación Publicada
6 estudios revisados por pares de PubMed. Haz clic en cualquier PMID para ver el estudio completo.
The effects of human growth hormone in men over 60 years old
Rudman D, Feller AG, Nagraj HS, et al. — New England Journal of Medicine (1990)
Hallazgo Clave: Landmark study: 6 months of rhGH in elderly men increased lean body mass by 8.8%, decreased adipose tissue by 14.4%, and increased lumbar vertebral bone density by 1.6%.
Two years of growth hormone (GH) treatment increase isometric and isokinetic muscle strength in GH-deficient adults
Jorgensen JO, Thuesen L, Muller J, et al. — Journal of Clinical Endocrinology & Metabolism (1989)
Hallazgo Clave: Two years of GH replacement significantly increased isometric quadriceps strength, lean body mass, and exercise capacity while reducing fat mass in GH-deficient adults.
Growth hormone replacement in healthy older men improves body composition but not functional ability
Papadakis MA, Grady D, Black D, et al. — Annals of Internal Medicine (1996)
Hallazgo Clave: 6 months of GH replacement increased lean body mass by 4.3% and decreased fat mass by 13.1% in healthy older men. Important caveat: functional strength did not significantly improve without resistance training.
Effects of growth hormone on body composition in adults with growth hormone deficiency: a meta-analysis
Hazem A, Elamin MB, Bancos I, et al. — Journal of Clinical Endocrinology & Metabolism (2012)
Hallazgo Clave: Meta-analysis of 54 studies: GH replacement decreased fat mass (−2.56 kg), increased lean mass (+2.69 kg), reduced LDL cholesterol, and improved quality of life in GH-deficient adults.
Recombinant human growth hormone replacement therapy in the elderly: a systematic review
Liu H, Bravata DM, Olkin I, et al. — Annals of Internal Medicine (2007)
Hallazgo Clave: Systematic review of 31 studies: GH increased lean body mass by 2.1 kg and decreased fat mass by 2.1 kg. Side effects included edema, arthralgias, carpal tunnel syndrome, and insulin resistance.
Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency
Gotherstrom G, Bengtsson BA, Bosaeus I, et al. — European Journal of Endocrinology (2007)
Hallazgo Clave: 10 years of GH replacement progressively increased bone mineral content and BMD at both the lumbar spine and femoral neck, with continued improvement beyond 5 years.
Potencia tu Protocolo de Investigación
4 SinergiasLa investigación sugiere combinar HGH con estos péptidos para mecanismos complementarios.
Ipamorelin stimulates endogenous GH release through GHSR, complementing exogenous HGH by maintaining pituitary responsiveness.
Preserves pituitary function during exogenous GH use. Allows lower HGH doses while maintaining IGF-1 output.
BPC-157 upregulates growth hormone receptors up to 7-fold, amplifying the tissue-level effects of circulating GH.
Dramatically enhanced tissue repair — HGH provides the signal while BPC-157 amplifies the receptor response at injury sites.
IGF-1 LR3 provides direct IGF-1 receptor activation, bypassing the hepatic conversion step and complementing HGH's indirect IGF-1 production.
Maximizes the anabolic arm of the GH/IGF-1 axis. Particularly effective for muscle hypertrophy and recovery protocols.
Mod GRF 1-29 stimulates GHRH receptors on the pituitary, supporting endogenous GH pulsatility alongside exogenous supplementation.
Prevents pituitary downregulation during HGH cycles. Smoother transition when tapering exogenous GH.
Especificaciones
Cómo Funciona HGH
HGH is a 191-amino acid protein synthesized in the anterior pituitary that binds to growth hormone receptors (GHR) on target tissues, triggering JAK2/STAT5 signaling. It stimulates hepatic IGF-1 production, which mediates many of its growth-promoting effects. HGH directly promotes lipolysis, protein synthesis, and glucose homeostasis. It acts on bone, muscle, liver, and adipose tissue to regulate growth, body composition, and metabolism throughout the lifespan.
Aplicaciones de Investigación
Precios
| Tamaño | Por Vial | Paquete de 10 |
|---|---|---|
6iu | $50.00 | $425.00 |
8iu | $60.00 | $510.00 |
10iu | $70.00 | $595.00 |
12iu | $80.00 | $680.00 |
15iu | $90.00 | $765.00 |
24iuMejor Valor | $120.00 | $1020.00 |
Precios de paquete de 10 mostrados. Descuentos por volumen para 50+ viales — contáctenos.
Certificado de Análisis
Este COA es una muestra representativa. Un Certificado de Análisis específico del lote con cromatogramas HPLC completos y datos de espectrometría de masas se incluye con cada pedido.
Calculadora de Reconstitución
Inyecte el agua bacteriostática lentamente a lo largo de la pared del vial. Agite suavemente hasta disolver — nunca sacuda. Almacene la solución reconstituida a 2-8°C y use dentro de 30 días.
Reseñas de Clientes
Preguntas Frecuentes
Seguridad y Advertencias
Not for use without medical supervision
HGH is a controlled substance in many jurisdictions. Research-grade peptides are not FDA-approved for human use. All information is for research and educational purposes.
Cancer risk — contraindicated with active malignancy
GH and IGF-1 promote cell proliferation. Contraindicated in patients with active cancer or history of malignancy. Epidemiological data shows elevated IGF-1 associated with increased cancer risk.
Insulin resistance and glucose dysregulation
GH is a counter-regulatory hormone to insulin. Chronic supraphysiological doses can induce insulin resistance, impaired glucose tolerance, and in rare cases, overt diabetes. Monitor fasting glucose and HbA1c.
Solo para Fines de Investigación y Educación. No es consejo médico. No para consumo humano. Consulte a un médico autorizado antes de tomar cualquier decisión relacionada con la salud.
Péptidos Relacionados
Up to 37% OffHGH Fragment 176-191
Estudiado para lipólisis dirigida sin efectos de crecimiento
CJC1295 with DAC
Estudiado para soporte sostenido de GH con dosificación semanal
Up to 40% OffCJC 1295 (without DAC)
Estudiado para la liberación pulsátil de GH imitando el ritmo natural
CJC 1295 5mg + IPA 5mg
El péptido estándar de oro estudiado para la optimización de GH